Titan Biotech AAQS
Delisted·Sep 16, 2026
The The AAQS of Titan Biotech (524717.BO) as of Oct 17, 2026 is 9. In the previous year, The AAQS was 9.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
9
YoY
0.00%
Last updated:
Titan Biotech has a current AAQS of 9.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Titan Biotech in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Titan Biotech in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Titan Biotech AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2019
9.00 INR
Jan 1, 2020
9.00 INR
Jan 1, 2021
9.00 INR
Jan 1, 2022
9.00 INR
Jan 1, 2023
9.00 INR
Jan 1, 2024
9.00 INR
Jan 1, 2025
9.00 INR
Jan 1, 2026
9.00 INR
| YEAR | AAQS | YoY |
|---|---|---|
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | 0.00% | |
| 9 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Titan Biotech Stock analysis
What does Titan Biotech do? Titan Biotech Ltd is a holding company headquartered in Delhi, India, listed on the stock exchange on 2 January 1995. With a workforce of 396 employees, the firm operates within the Materials sector, specifically in the Chemicals industry. It functions as a manufacturer and exporter of biological products for various industries, including pharmaceuticals, nutraceuticals, food and beverages, biotechnology, cosmetics, veterinary care, animal feed, and agriculture. The company produces peptones, biological extracts, culture media, and chemicals. Its product portfolio spans food ingredients like hydrolyzed vegetable protein and yeast extract, as well as collagen and proteins such as soya protein isolate and collagen peptides. Titan Biotech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Titan Biotech stock
The AAQS of Titan Biotech is 9 in 2026.
On Eulerpool you can find the complete historical development of The AAQS Titan Biotech since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Titan Biotech
All Key Metrics — Titan Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth